Pristimerin, a traditional Chinese medicine, significantly decreased the AEG-1, FANCD2 and FANCI levels in endometrial cancer cells and restored their sensitivity to cisplatin in an in vivo xenograft model [184]. Here, FANCI is linked to endometrial cancer.